C07K 16/1145
Env proteins
Official title: {Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site}
C07K16/1145 (Env proteins) appears on 624 US grants and 794 published applications in this corpus.
Search patents in C07K- Granted patents
- 624
- Published applications
- 794
- Assignees
- 423
- Inventors
- 1,308
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 2 | 0 |
| 1990 | 2 | 0 |
| 1991 | 2 | 0 |
| 1992 | 2 | 0 |
| 1993 | 6 | 0 |
| 1994 | 7 | 0 |
| 1995 | 4 | 0 |
| 1996 | 10 | 0 |
| 1997 | 19 | 0 |
| 1998 | 27 | 0 |
| 1999 | 22 | 0 |
| 2000 | 23 | 0 |
| 2001 | 21 | 3 |
| 2002 | 17 | 10 |
| 2003 | 10 | 24 |
| 2004 | 6 | 26 |
| 2005 | 10 | 19 |
| 2006 | 13 | 22 |
| 2007 | 7 | 24 |
| 2008 | 11 | 23 |
| 2009 | 10 | 21 |
| 2010 | 12 | 28 |
| 2011 | 7 | 33 |
| 2012 | 23 | 32 |
| 2013 | 10 | 27 |
| 2014 | 21 | 35 |
| 2015 | 19 | 41 |
| 2016 | 24 | 46 |
| 2017 | 23 | 40 |
| 2018 | 38 | 34 |
| 2019 | 36 | 43 |
| 2020 | 30 | 45 |
| 2021 | 40 | 43 |
| 2022 | 18 | 32 |
| 2023 | 26 | 40 |
| 2024 | 23 | 44 |
| 2025 | 27 | 33 |
| 2026 | 16 | 26 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Cell-receptor targeted exosomes6 Oct 2026US 12,751,930 B2City of Hope
- Immunostimulatory adjuvants6 Oct 2026US 12,752,000 B2Orionis Biosciences BV
- Rapid elicitation of broadly neutralizing bovine antibodies to HIV Env25 Aug 2026US 12,715,907 B2International AIDS Vaccine Initiative
- Methods and compositions for engineering CD4-deficient CAR T cells and anti-CD4 CAR T cells and uses thereof11 Aug 2026US 12,703,735 B2Seattle Children's Hospital
- Broadly neutralizing antibodies against HIV2 Jun 2026US 12,643,940 B2Universität zu Köln
- Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof17 Sep 2026US 2026/0274995 A1ModeX Therapeutics, Inc.
- Dual-germline antibody engager hiv-1 envelope chimeric immunogens27 Aug 2026US 2026/0248907 A1The United States of America, as represented by the Secretary, Department of Health and Human Services
- Recombinant hiv env polypeptides and their use27 Aug 2026US 2026/0250331 A1International AIDS Vaccine Initiative
- Assays and reagents for the detection of soluble gp12027 Aug 2026US 2026/0251654 A1
- Multispecific anti-hiv antibodies20 Aug 2026US 2026/0242449 A1International AIDS Vaccine Initiative
Most cited
By later US patents
- Anti-PD-L1 antibodies, compositions and articles of manufacture459US 8,217,149 B2Genentech, Inc. · 2012
- Cells producing antibody compositions with increased antibody dependent cytotoxic activity247US 6,946,292 B2Kyowa Hakko Kogyo Co., Ltd. · 2005
- Multispecific chimeric receptors174US 6,103,521 ACell Genesys, Inc. · 2000
- Multivalent and multispecific binding proteins and their use144US 6,492,123 B1Medical Research Council · 2002
- Methods for producing antibody libraries using universal or randomized immunoglobulin light chains130US 5,667,988 AThe Scripps Research Institute · 1997